The distinctive formulation of ondansetron was developed leveraging MonoSol Rx’s PharmFilm technology.
Company relaunched Zuplenz, the first oral soluble lingual film product cleared by FDA as a prescription medication, in the fourth quarter of 2012 in the US.
MonoSol Rx president and CEO Mark Schobel said, "We know that this oral film delivery of the drug ondansetron fulfills a significant unmet need, as we have fielded a continuous stream of inquiries from doctors and nurses regarding the availability of Zuplenz."
According to the deal, Vestiq will make an undisclosed upfront payment to MonoSol Rx, which is also eligible for Zuplenz sales-based royalty payments.
Vestiq Pharmaceuticals Chairman and CEO Martin Baum said, "The oral film delivery technology is a major breakthrough for ease of use and compliance for supportive care patients, who consistently have difficulty swallowing."